Johnson & Johnson (NYSE:JNJ) Shares Bought by Nuance Investments LLC

Nuance Investments LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 44.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 224,711 shares of the company’s stock after buying an additional 69,225 shares during the quarter. Johnson & Johnson accounts for approximately 1.3% of Nuance Investments LLC’s holdings, making the stock its 27th biggest holding. Nuance Investments LLC’s holdings in Johnson & Johnson were worth $31,298,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Crewe Advisors LLC increased its position in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares in the last quarter. Evolution Wealth Advisors LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth about $40,000. Permanens Capital L.P. increased its position in Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares in the last quarter. Thor Advisors LLC purchased a new stake in Johnson & Johnson during the 1st quarter worth about $69,000. Finally, Personal Wealth Partners purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $73,000. Institutional investors and hedge funds own 72.12% of the company’s stock.

Get Johnson & Johnson alerts:

NYSE:JNJ traded down $0.69 during mid-day trading on Thursday, reaching $130.48. The company’s stock had a trading volume of 295,137 shares, compared to its average volume of 7,115,274. The company’s fifty day simple moving average is $130.11 and its two-hundred day simple moving average is $135.97. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The stock has a market cap of $335.04 billion, a P/E ratio of 15.95, a P/E/G ratio of 2.15 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period last year, the company earned $2.10 EPS. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s payout ratio is 46.45%.

A number of research firms recently commented on JNJ. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective for the company. in a research report on Thursday, July 18th. Morgan Stanley reiterated an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Bank of America reiterated a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Credit Suisse Group set a $156.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Buy” and an average target price of $150.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.